A Pill 'Melts Away' Common Form Of Leukemia RedOrbit They found that those who received the combination of idelalsib and rituximab went longer without their disease worsening than those who received only rituximab, which has been the standard of care. Six months into the study, cancers in 93 percent of ... |
